Telomerase activity, estrogen receptors (α, β), Bcl-2 expression in human breast cancer and treatment response

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Murillo Ortiz, Blanca ^a   Astudillo De la Vega, Horacio ^a   Castillo Medina, Sebastian ^a   Malacara, J M ^b   Benitez Bribiesca, Luis ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUANAJUATO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUOROURACIL; MOLECULAR MARKER; PROTEIN BCL 2; TELOMERASE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INVASIVE CARCINOMA; MASTECTOMY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TREATMENT RESPONSE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLUOROURACIL; HELA CELLS; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TELOMERASE; TREATMENT OUTCOME;

EID: 33748643227     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-206     Document Type: Article

References (43)

1. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-91.
2. Holt SF, Shay JW: Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999, 180:10-18.
3. Shpitz B, Zimlichman S, Zemer R, Bomstein Y, Zehavi T, Liverant S, Bernehim J, Kaufman Z, Klein E, Shapira Y, Klein A: Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 1999, 58:65-69.
4. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F: Telomerase activation by hTER in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998, 18:65-68.
5. Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK: Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. Mol Cancer Res 2005, 9:503-9.
6. Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A: Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 1996, 32A:1148-55.
7. Marsh KL, Varley JM: Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br J Cancer 1998, 77:1460.
8. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 22;348(6299):334-6.
9. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM: DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc Nat Acad Sci USA 1987, 84:1329-1331.
10. Dueñas-Gonzalez A, Abad-Hernandez, Cruz-Hernandez J, Gonzalez-Sarmiento R: Analysis of Bcl-2 in sporadic breast carcinoma. Cancer 1997, 80:2100-2108.
11. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998, 82:1296-1302.
12. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN, Allasia C: Automated and quantitative immunohistochemical assays of bcl-2 protein in breast carcinomas. Br J Cancer 1997, 76:340-346.
13. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: a prognosis indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Nat Cancer Inst 1994, 86:499-504.
14. Bhargava V, Kell DL, van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145:535-539.
15. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 1994, 145(5):1191-1198.
16. Leek RD, Kaklamanis L, Pezzella F: Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994, 69:135-139.
17. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ: Expresión of bcl-2 in node-negative breast cancer is associated with various prognosis factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996, 74:78-85.
18. Wu J, Shao ZM, Shen ZZ, Lu JS, Han QX, Fontana JA, Barsky SH: Significance of apoptosis and apoptotic-related proteins, Bcl-2 and Bax in primary breast cancer. Breast J 2000, 6:44-52.
19. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995, 60:54-60.
20. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, Piaggio G, Sacchi A, Pontecorvi A, Bacchetti S, Farsetti A: Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells. Mol Cell Biol 2000, 20(11):3764-71.
21. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M: Estrogen activates telomerase. Cancer Res 59(23):5917-21. 1999 Dec 1
22. Kalogeraki A, Kafousi M, Ieromonachou P, Giannikaki E, Vrekoussis T, Zoras O, Tsiftsis D, Stathopoulos E: Telomerase activity as a marker of invasive ductal breast carcinomas on FNABs and relationship to other prognostic variables. Anticancer Res 2005, 25(3B):1927-30.
23. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein Lonning P: Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001, 7:1230-1236.
24. Gollahon LS, Holt SE: Alternative methods of extracting telomerase activity from human tumor simples. Cancer Lett 2000, 159:141-149.
25. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-5.
26. Qiu Cunping, Shan Liang, Yu Minshu and Snyderwine Elizabeth G: Steroid hormone receptor expression and proliferation in ratmammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine. Carcinogenesis 2005, 26(4):763-769.
27. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995, 1(3):249-55.
28. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama : Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 55(13):2734-6. 1995 Jul 1
29. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 55(12):2533-6. 1995 Jun 15
30. Campisi J, Kim Sh, Lim Ch S, Rubio M: Cellular senescence, cancer and aging: the telomere connection. Exp Geront 2000, 36:1619-1637.
31. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537-41. 2001 Mar 15
32. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P: Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004, 11:537-551.
33. Dotzlaw H, Leygue E, Watson PH, Murphy LC: Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 59(3):529-32. 1999 Feb 1
34. Speirs V, Kerin MJ: Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 2000, 87(4):405-9.
35. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA: Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 2002, 198(4):450-7.
36. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, Wolczynski S: Distinct mRNA, protein expression patterns and distribution of oestrogen receptors a and b in human primary breast cancer: Correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 2005, 41:2924-2934.
37. Hayashi S, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yosida N, Yamaguchi Y: The expressión and function of estrogen receptor α and β in human breast cancer and its clinical application. Endoc Relat Cancer 2003, 10:193-202.
38. Leyegue E, Dotzlaw H, Watson PH, Murphy LC: Expression of estrogen receptor beta1, beta2, and beta 5 messenger RNAs in human breast tissue. Cancer Res 59(6):1175-9. 1999 Mar 15
39. Baykal A, Rosen D, Zhou C, Liu J, Shin AA: Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 2004, 11(5):262-8.
40. Takahashi M, Kigawa J, Oishi T, Itamochi H, Shimada M, Sato S, Kamazawa S, Akeshima R, Terakawa N: Alteration of telomerase activity in ovary cancer after chemotherapy. Gynecol Obstet Invest 2000, 49:204-208.
41. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A: Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: Correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998, 18:1465-1472.
42. Ward RJ, Autexier C: Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005, 68(3):779-786.
43. Buttitta F, Pelligrini C, Marchetti A, Gadducci A, Cosio S: Human Telomerase Reverse Transcriptase mRNA Expresion Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma. J Clin Oncol 2003, 21(7):1320-1325.